文献速递胸部肿瘤

阿得贝利单抗或安慰剂联合卡铂和依托泊苷一线治疗广泛期小细胞肺癌(CAPSTONE-1):多中心、随机、双盲、安慰剂对照、3期试验

Adebrelimab or placebo plus carboplatin and etoposide as first-line treatment for extensive-stage small-cell lung cancer (CAPSTONE-1): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial.
PubMed 文献 · Lancet Oncol · 2022-05-13

CAPSTONE-1研究在中国47家三级医院纳入462例既往未经治疗的广泛期小细胞肺癌患者,随机接受阿得贝利单抗或安慰剂联合卡铂和依托泊苷一线治疗。阿得贝利单抗组中位总生存期显著优于安慰剂组(15.3个月 vs 12.8个月,HR 0.72,单侧P=0.0017),安全性可接受。

要点

  • 阿得贝利单抗联合化疗较安慰剂联合化疗显著改善广泛期小细胞肺癌患者总生存期。
  • 阿得贝利单抗组中位总生存期15.3个月,安慰剂组12.8个月,HR 0.72。
  • 两组≥3级治疗相关不良事件最常见为中性粒细胞计数降低、白细胞计数降低、血小板计数降低和贫血。

核心结论

  • 在广泛期小细胞肺癌患者中,化疗联合阿得贝利单抗较化疗联合安慰剂显著改善总生存期,且安全性可接受,支持该联合方案作为该人群新的一线治疗选择。

研究设计与样本

  • CAPSTONE-1是一项在中国47家三级医院开展的随机、双盲、安慰剂对照、3期试验。
  • 纳入年龄18-75岁、既往未经治疗的组织学或细胞学确诊的广泛期小细胞肺癌、ECOG体能状态评分0-1的患者。
  • 共462例合格患者按1:1随机分配接受阿得贝利单抗联合化疗(230例)或安慰剂联合化疗(232例)。
  • 治疗方案为4-6周期卡铂(曲线下面积5 mg/mL/min,每周期第1天)和依托泊苷(100 mg/m2体表面积,每周期第1-3天)联合阿得贝利单抗(20 mg/kg,每周期第1天)或匹配安慰剂,随后阿得贝利单抗或安慰剂维持治疗,均为21天周期静脉给药。
  • 主要终点为至少接受一剂研究药物患者的总生存期,安全性在按治疗分析人群中分析。

主要发现

  • 数据截止2021年10月8日,中位随访13.5个月(IQR 8.9-20.1)。
  • 阿得贝利单抗组中位总生存期15.3个月(95%CI 13.2-17.5),安慰剂组12.8个月(95%CI 11.3-13.7),HR 0.72(95%CI 0.58-0.90),单侧P=0.0017。
  • 最常见的治疗相关3或4级不良事件为中性粒细胞计数降低(阿得贝利单抗组174例[76%] vs 安慰剂组175例[75%])、白细胞计数降低(106例[46%] vs 88例[38%])、血小板计数降低(88例[38%] vs 78例[34%])和贫血(64例[28%] vs 66例[28%])。
  • 治疗相关严重不良事件发生在阿得贝利单抗组89例(39%)和安慰剂组66例(28%)。
  • 治疗相关死亡共4例:阿得贝利单抗组2例(呼吸衰竭和间质性肺病及肺炎),安慰剂组2例(多器官功能障碍和不明原因死亡)。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Extensive-stage small-cell lung cancer (ES-SCLC) is associated with poor prognosis and treatment options are scarce. Immunotherapy has shown robust clinical activity in ES-SCLC in previous phase 3 trials. We aimed to assess the efficacy and safety of adebrelimab (SHR-1316), a novel anti-PD-L1 antibody, with standard chemotherapy as a first-line treatment for ES-SCLC. METHODS: The CAPSTONE-1 study was a randomised, double-blind, placebo-controlled, phase 3 trial, done in 47 tertiary hospitals in China. Key inclusion criteria were patients aged 18-75 years, with previously untreated histologically or cytologically confirmed ES-SCLC and an Eastern Cooperative Oncology Group (ECOG) performance status of 0-1. Eligible patients were randomly assigned (1:1) to receive four to six cycles of carboplatin (area under the curve of 5 mg/mL per min, day 1 of each cycle) and etoposide (100 mg/m2 of body-surface area, on days 1-3 of each cycle) with either adebrelimab (20 mg/kg, day 1 of each cycle) or matching placebo, followed by maintenance therapy with adebrelimab or placebo. All treatments were given intravenously in 21-day cycles. Randomisation was done using a centralised interactive web response system with a block size of four, stratified by liver metastases, brain metastases, and lactate dehydrogenase concentration. The primary endpoint was overall survival in patients who received at least one dose of study medication. Safety was analysed in the as-treated population. This study is complete and registered with ClinicalTrials.gov, NCT03711305. FINDINGS: Between Dec 26, 2018, and Sept 4, 2020, 462 eligible patients were enrolled and randomly assigned: 230 (50%) patients received adebrelimab plus chemotherapy (adebrelimab group) and 232 (50%) patients received placebo plus chemotherapy (placebo group). At data cutoff (Oct 8, 2021), median follow-up was 13·5 months (IQR 8·9-20·1). Median overall survival was significantly improved in the adebrelimab group (median 15·3 months [95% CI 13·2-17·5]) compared with the placebo group (12·8 months [11·3-13·7]; hazard ratio 0·72 [95% CI 0·58-0·90]; one-sided p=0·0017). The most common treatment-related grade 3 or 4 adverse events were decreased neutrophil count (174 [76%] patients in the adebrelimab group and 175 [75%] patients in the placebo group), decreased white blood cell count (106 [46%] and 88 [38%]), decreased platelet count (88 [38%] and 78 [34%]), and anaemia (64 [28%] and 66 [28%]). Treatment-related serious adverse events occurred in 89 (39%) patients in the adebrelimab group and 66 (28%) patients in the placebo group. Four treatment-related deaths were reported: two each in the adebrelimab group (respiratory failure and interstitial lung disease and pneumonia) and placebo group (multiple organ dysfunction and unknown cause of death). INTERPRETATION: Adding adebrelimab to chemotherapy significantly improved overall survival with an acceptable safety profile in patients with ES-SCLC, supporting this combination as a new first-line treatment option for this population. FUNDING: Jiangsu Hengrui Pharmaceuticals.

来源:Lancet Oncol,查看原文。版权归原作者所有。

引用

  1. Wang J, Zhou C, Yao W, et al. Adebrelimab or placebo plus carboplatin and etoposide as first-line treatment for extensive-stage small-cell lung cancer (CAPSTONE-1): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 2022. PMID: 35576956. doi:10.1016/S1470-2045(22)00224-8

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。